Skip to content
Home » Artish Co., Ltd. Announcement of the establishment of Artish Co., Ltd., a regenerative medicine design company

Artish Co., Ltd. Announcement of the establishment of Artish Co., Ltd., a regenerative medicine design company

Artish Co., Ltd.
Announcement of establishment of Artish Co., Ltd., a regenerative medicine design company
We are pleased to announce that Shinichi Sakurada (Representative Director, President and CEO) and Kosei Senmoto (Representative Director and Chairman), a serial entrepreneur and rare manager, have jointly established Artissue Inc. (English name: Artissue Inc.). ……
Today, December 8, 2023, Shinichi Sakurada (Representative Director, President and CEO) and Kosei Senbon (Representative Director and Chairman), a serial entrepreneur and rare manager, jointly established Artissue Inc. I will let you know what I have done.
In regenerative medicine and its related industries, which have become chaotic due to the confusion, we aim to continuously design
businesses, products, and services by making full use of Japan’s strength, the Japanese spirit, and the world’s most advanced artificial intelligence (AI). We will weave a pattern of mechanical, efficient, and exquisite regenerative medicine.
Company name: Artissue Inc. (English name: Artissue Inc.)
Location: 3F Nippon Life Marunouchi Garden Tower, 1-1-3 Marunouchi, Chiyoda-ku, Tokyo
HP: http://artissue.net
Established: December 8, 2023
Capital: 10 million yen
Representative: Shinichi Sakurada, Representative Director, President and CEO Representative Director and Chairman Sachio Senmoto
Greetings from the representative
Representative Director and Chairman Kosei Senbon
Our new company is ready to take a breakthrough step in the field of regenerative medicine. This is not just the beginning of a business; we aim to contribute to a sustainable society and provide hope to many patients with congenital and other intractable diseases.
In the past, I have experienced how encounters with people have had a great impact on my life, such as the encounter with Kazuo Inamori and others that led to the co-founding of Daini Denden (currently KDDI). Thanks to my encounter with Mr. Sakurada at my alma mater, the University of Florida, I was able to embark on this new challenge together, marking another major milestone. By combining Mr. Sakurada’s extensive knowledge and experience in regenerative medicine and its border areas with my past experience, we will utilize AI technology to realize innovative medical solutions.
Our mission is to lead the regenerative medicine industry and create new value using cutting-edge AI technology. With the support of our team and all of you, we are achieving our mission of “Aiming for a sustainable society and making the next generation happy with the regenerative organ revolution.”
As we begin this new journey, we ask for your continued support and trust. Representative Director, President and CEO Shinichi Sakurada Regenerative medicine exists in a boundary area spanning science, engineering, and medicine, and has required a wide range of
specialized knowledge and experience. Due to the huge amount of information, experts in various specialized fields have attempted to industrialize it, but there are few successful examples, and the current situation is that regenerative medicine and related industries have not yet developed. However, the information revolution in AI technology, including generative AI, has shed light on this situation. The boundary area where the physical domain and the AI ​​domain overlap has further expanded, but we are confident that we can provide innovative solutions by carefully connecting these areas one by one. We will skillfully design the “manufacturing capabilities” and “detailed service provision capabilities” of each Japanese company, and weave a value chain from upstream materials and parts to midstream system integration and downstream regenerative medical service provision, with AI as the main focus. We believe that by implementing these measures, we will be able to generate continuous profits for each company and provide the best services to patients. Additionally, by automating all processes and building an environment for efficient manufacturing and cell processing, we will promote the development of regenerative medicine and related industries in Japan and contribute to long-term reductions in medical costs. . Through these efforts, we will provide innovative medical care to patients around the world with congenital diseases that cannot be resolved with conventional medical care.
We aim for accelerated growth by leveraging our connections with the information industry around the world and seamlessly designing both real and information spaces. Additionally, the University of Florida, Sakurada and Senmoto’s alma mater, will utilize the No. 1 AI facility at a university in the United States, which was established with a donation of over $100 million from Mr. Malachowsky, one of the founders of NVIDIA, and Senmoto. We will promote cooperation between Japan and the United States. Through these designs in the field of regenerative medicine, we will achieve our mission of “Aiming for a sustainable society and making the next generation happy with a regenerative organ revolution.”
[Image

https://prtimes.jp/main/html/rd/p/000000001.000134279.html



%d